Panacea Biotec Reports Widened Losses Despite Revenue Growth in Q2 FY2026

Panacea Biotec , a leading biotechnology company, has reported a significant increase in losses for the quarter ended September 30, 2025, despite a rise in total income. The company's financial results, released on November 14, 2025, reveal a complex picture of growth and challenges.

Financial Highlights

Net Loss: Panacea Biotec posted a net loss of ₹1,563.00 lakh for Q2 FY2026, compared to a loss of ₹668.00 lakh in the same quarter last year.
Total Income: The company's total income rose to ₹9,442.00 lakh in Q2 FY2026 from ₹8,005.00 lakh in Q2 FY2025.
Revenue from Operations: Increased to ₹9,081.00 lakh in Q2 FY2026 from ₹7,664.00 lakh in Q2 FY2025.

Segment Performance

The company's financial results show a mixed performance across its two main segments:

Segment	Q2 FY2026 Revenue (₹ Lakh)	Q2 FY2026 Profit/(Loss) (₹ Lakh)
Vaccines	9,081.00	(1,657.00)
Formulations	5,032.00	(260.00)

Exceptional Income

During the half-year period ended September 30, 2025, Panacea Biotec recognized exceptional income of ₹1,402.00 lakh, which included:

₹858.00 lakh from a settlement agreement with Apotex Inc., USA.
₹544.00 lakh from deferred consideration on the sale of domestic pharmaceutical brands.

Management's Perspective

Despite the increased losses, the management remains optimistic about the company's future. They cited several factors supporting their going concern basis:

Surplus funds from the sale of pharmaceutical formulations brands in India and Nepal in March 2022.
Strengthened working capital position.
Setting up new facilities for enhancing vaccine drug substance manufacturing capacities.
Scaling up nutrition and pharmaceutical formulations business.
Higher long-term business orders for vaccines from key institutional customers.

Looking Ahead

While the widened losses are a concern, Panacea Biotec's increased revenue and exceptional income suggest potential for future growth. The company's focus on expanding its vaccine manufacturing capabilities and diversifying its product portfolio may help in improving its financial performance in the coming quarters.

Investors and stakeholders will be watching closely to see how Panacea Biotec navigates these challenges and capitalizes on its growth initiatives in the biotechnology and pharmaceutical sectors.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.17%	-3.56%	-10.09%	-29.38%	+11.78%	+111.50%

Panacea Biotec , a prominent player in the Indian pharmaceutical sector, has announced a significant development in its vaccine business. The company has secured a substantial order for its Easyfive-TT vaccine, marking a notable achievement in its long-term growth strategy.

Contract Details

Aspect	Details
Contract Value	$4.75 million (~₹41 Crore)
Supply Period	Calendar Years 2026 and 2027
Awarding Entity	Pan American Health Organization (PAHO)
Product	Easyfive-TT (DTP-HepB-Hib) Vaccine

Key Highlights

Long-Term Agreement: The contract is part of a Long-Term Agreement (LTA) with PAHO, valid until December 31, 2027.
Product Specifics: Easyfive-TT is a pentavalent vaccine, combining protection against Diphtheria, Tetanus, Pertussis, Hepatitis B, and Haemophilus influenzae type B.
International Reach: This order reinforces Panacea Biotec's position in the international vaccine market, particularly in the Americas.

Implications for Panacea Biotec

This contract represents a significant revenue opportunity for Panacea Biotec's vaccine business segment. The long-term nature of the agreement provides the company with a stable revenue stream for the specified period, potentially enhancing its financial stability and market position.

Market Response

While the immediate market response to this news is yet to be seen, such long-term contracts often contribute positively to investor confidence. The ability to secure international contracts of this magnitude may be viewed as a testament to the quality and competitiveness of Panacea Biotec's vaccine products.

Looking Ahead

As Panacea Biotec prepares to fulfill this substantial order, stakeholders will likely be watching for any updates on the company's production capacity, delivery timelines, and potential for similar contracts in the future. This development may also spark interest in the company's overall growth strategy and its position in the global vaccine market.

The successful execution of this contract could pave the way for more international opportunities, potentially strengthening Panacea Biotec's foothold in the competitive pharmaceutical industry.